The First WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses
24–26 January 2013, Hong Kong Baptist University, Hong Kong SAR, China
Background, meeting objectives and expected outcome
One of the objectives of the IVB department is to promote the development of influenza vaccines that induce broadly protective and long lasting immune responses. These novel vaccines would overcome problems with the current vaccination strategy and likely be more acceptable in developing countries.
Such vaccines would also contribute to the control of epidemics and potential pandemics. During 2004-2011, IVR convened eleven meetings on the development and evaluation of novel influenza vaccines. The technical reports of each of these conferences were published in leading journals.
Last year, IVR decided to combine its annual meeting on clinical trials evaluating pandemic influenza vaccines with its biennial meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses.
The meeting was organized as a joint activity of WHO, the Wellcome Trust, UK, the Institute of Creativity and the Carter Centre at the Hong Kong Baptist University and was fully funded by the CDC-WHO Collaborative Agreement, a meeting grant from the Wellcome Trust and financial (including services in-kind) support from the Institute of Creativity and the Carter Centre at the Hong Kong Baptist University.
- review the current status of research in the area of new influenza vaccines, focusing on strategies to induce broadly protective and long-lasting immune responses;
- discuss recent data from clinical trials of pandemic and seasonal influenza vaccines; and
- define a research agenda for the accelerated development of novel influenza vaccines.
- research agenda for the accelerated development of cross protective influenza vaccines and
- publication of a technical report in the peer-reviewed literature.